Other Information
−Removed: Not applicable.
+Added: During the three months ended June 30, 2023, none of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) adopted , terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).
The following is a list of exhibits filed as part of this Quarterly Report on Form 10-Q.
1 unchanged sentence
For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated in parentheses.
−Removed: Agreement and Plan of Merger, dated as of February 8, 2023, by and among NuVasive, Inc., Globus Medical, Inc.
−Removed: and Zebra Merger Sub, Inc.
−Removed: (incorporated by reference to Exhibit 2.1 of the Registrant’s Form 8-K, filed with the SEC on February 9, 2023).
−Removed: Voting and Support Agreement, dated as of February 8, 2023, by and among NuVasive, Inc., Globus Medical, Inc., David C.
−Removed: Paul and Sonali Paul (incorporated by reference to Exhibit 10.1 of the Registrant’s Form 8-K, filed with the SEC on February 9, 2023).
+Added: 2021 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on June 8, 2023).
Certification by Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
15 unchanged sentences
GLOBUS MEDICAL, INC.
+Added: August 3, 2023
/s/ DANIEL T.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 3, 2023
/s/ KEITH PFEIL
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.